Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Hepsulfam is an anticancer agent. It also displays excellent antileukemic activity (a median IC50: 0.91 μg/mL in a panel of different tumors).
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 1,210 | 5日内发货 | ||
25 mg | ¥ 6,760 | 6-8周 | ||
50 mg | ¥ 8,790 | 6-8周 | ||
100 mg | ¥ 13,600 | 6-8周 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,650 | 5日内发货 |
产品描述 | Hepsulfam is an anticancer agent. It also displays excellent antileukemic activity (a median IC50: 0.91 μg/mL in a panel of different tumors). |
靶点活性 | Tumors:0.91 μg/ml |
体外活性 | Hepsulfam is more toxic to L1210 leukemia cells than is busulfan, its structural homologue. Consistent with the difference in toxicity, hepsulfam induces DNA interstrand cross-links in L1210 mouse leukemia cells, whereas busulfan does not. Hepsulfam is more cytotoxic to two human leukemia cell lines (111-60 and K562) and to two human colon carcinoma cell lines (BE and HT-29) than is busulfan. As in 11210 cells, hepsulfam causes a higher level of DNA interstrand cross-links than busulfan. Hepsulfam (1.0 μg/mL) is active in eight of 37 tumors (22%) in the clonogenic assay. Hepsulfam demonstrates a clear in vitro toxicity to human bone marrow cells (CFU-GM) from healthy donors. Evaluation of equitoxic concentrations in vitro shows a higher activity of hepsulfam, especially in non-small cell lung cancer[1]. Hepsulfam is also more cytotoxic to the human leukemia cell lines when the concentrations are reduced 10-fold and the duration of drug exposure is increased to 12 h[2]. |
体内活性 | The preclinical activity of hepsulfam shows a possible role of this compound in the treatment of solid human malignancies. Hepsulfam demonstrates superior in vivo activity in a large cell lung cancer xenograft and a gastric carcinoma model. The increased bone marrow toxicity of hepsulfam as compared with the busulfan might be critical for further clinical application[1]. |
别名 | NCI 329680, ZINC01574758 |
分子量 | 290.36 |
分子式 | C7H18N2O6S2 |
CAS No. | 96892-57-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Hepsulfam 96892-57-8 Others NCI 329680 ZINC-01574758 ZINC01574758 ZINC 01574758 NCI329680 NCI-329680 Inhibitor inhibitor inhibit